A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors.

被引：0
|
作者：
Segal, Neil Howard
Hodi, F. Stephen
Sanborn, Rachel E.
Gajewski, Thomas
Wolchok, Jedd D.
Urba, Walter John
Fox, Bernard A.
Topallan, Suzanne Louise
Pardoll, Drew M.
Kollia, Georgia
McDonald, Dan
Kim, Su Young
Sharfman, William Howard
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Earle A Chiles Res Inst & Providence Canc Ctr, Portland, OR USA
[3] Univ Chicago, Ctr Comprehens Canc, Chicago, IL 60637 USA
[4] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[5] Bristol Myers Squibb Co, Princeton, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3115
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial.
    Hodi, F. Stephen
    Sznol, Mario
    Kluger, Harriet M.
    McDermott, David F.
    Carvajal, Richard D.
    Lawrence, Donald P.
    Topalian, Suzanne Louise
    Atkins, Michael B.
    Powderly, John D.
    Sharfman, William Howard
    Puzanov, Igor
    Smith, David C.
    Leming, Philip D.
    Lipson, Evan J.
    Taube, Janis M.
    Anders, Robert
    Horak, Christine E.
    Kollia, Georgia
    Gupta, Ashok Kumar
    Sosman, Jeffrey Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [32] First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status.
    Gettinger, Scott N.
    Shepherd, Frances A.
    Antonia, Scott Joseph
    Brahmer, Julie R.
    Chow, Laura Quan Man
    Juergens, Rosalyn A.
    Borghaei, Hossein
    Shen, Yun
    Harbison, Christopher
    Alaparthy, Suresh
    Chen, Allen C.
    Rizvi, Naiyer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [33] Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).
    Sznol, Mario
    Kluger, Harriet M.
    Hodi, F. Stephen
    McDermott, David F.
    Carvajal, Richard D.
    Lawrence, Donald P.
    Topalian, Suzanne Louise
    Atkins, Michael B.
    Powderly, John D.
    Sharfman, William Howard
    Puzanov, Igor
    Smith, David C.
    Wigginton, Jon M.
    Kollia, Georgia
    Gupta, Ashok Kumar
    Sosman, Jeffrey Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18)
  • [34] Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Maintenance as Monotherapy or in Combination With Bevacizumab (BEV) for Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy
    Rizvi, N. A.
    Antonia, S. J.
    Shepherd, F. A.
    Chow, L. Q.
    Goldman, J.
    Shen, Y.
    Chen, A. C.
    Gettinger, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S32 - S32
  • [35] Phase II Study of Nivolumab (ONO-4538/BMS-936558) for Esophageal Cancer: Clinical activity by PD-L1 expression analysis
    Hara, Hiroki
    Kojima, Takashi
    Hironaka, Shuichi
    Kato, Ken
    Tsushima, Takahiro
    Ura, Takashi
    Doki, Yuichiro
    Ohtsu, Atsushi
    Hamamoto, Yasuo
    Kitagawa, Yuko
    ANNALS OF ONCOLOGY, 2016, 27
  • [36] A phase I study to evaluate safety and antitumor activity of biweekly BMS-936558 (Anti-PD-1, MDX-1106/ONO-4538) in patients with RCC and other advanced refractory malignancies
    McDermott, D. F.
    Drake, C. G.
    Sznol, M.
    Sosman, J. A.
    Smith, D. C.
    Powderly, J. D.
    Feltquate, D. M.
    Kollia, G.
    Gupta, A. K.
    Wigginton, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [37] Safety and Efficacy of First-Line Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC)
    Antonia, S. J.
    Gettinger, S.
    Goldman, J.
    Chow, L. Q.
    Juergens, R.
    Borghaei, H.
    Brahmer, J. R.
    Shen, Y.
    Harbison, C.
    Chen, A. C.
    Ready, N. E.
    Rizvi, N. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S32 - S33
  • [38] LONG-TERM SURVIVAL OF IPILIMUMAB-NAIVE PATIENTS WITH ADVANCED MELANOMA (MEL) TREATED WITH NIVOLUMAB (ANTI-PROGRAMMED DEATH-1; ANTI-PD-1; BMS-936558; ONO-4538) IN A PHASE I TRIAL
    Hodi, Stephen
    Sznol, Mario
    Kluger, Harriet M.
    McDermott, David F.
    Carvajal, Richard D.
    Lawrence, Donald P.
    Topalian, Suzanne L.
    Atkins, Michael B.
    Powderly, John D.
    Sharfman, William H.
    Puzanov, Igor
    Smith, David C.
    Leming, Philip D.
    Lipson, Evan J.
    Taube, Janis M.
    Anders, Robert A.
    Horak, Christine E.
    Kollia, Georgia
    Gupta, Ashok
    Sosman, Jeffrey A.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 177 - 177
  • [39] Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC)
    Antonia, S. J.
    Brahmer, J. R.
    Gettinger, S.
    Chow, L. Q.
    Juergens, R.
    Shepherd, F. A.
    Laurie, S. A.
    Gerber, D. E.
    Goldman, J.
    Shen, Y.
    Harbison, C.
    Chen, A. C.
    Borghaei, H.
    Rizvi, N. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S2 - S2
  • [40] Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC).
    Antonia, Scott Joseph
    Brahmer, Julie R.
    Gettinger, Scott N.
    Chow, Laura Quan Man
    Juergens, Rosalyn A.
    Shepherd, Frances A.
    Laurie, Scott Andrew
    Gerber, David E.
    Goldman, Jonathan Wade
    Shen, Yun
    Harbison, Christopher
    Alaparthy, Suresh
    Chen, Allen C.
    Borghaei, Hossein
    Rizvi, Naiyer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345